Valuation: GOLD SWAP

Market Cap 5.29M 4.62M 4.26M 3.92M 7.43M 509M 7.55M 50.9M 19.97M 249M 19.85M 19.42M 857M P/E 2024
-0.75x
P/E 2025 -0.67x
Enterprise Value -1.57M -1.37M -1.27M -1.17M -2.21M -151M -2.25M -15.14M -5.94M -73.94M -5.9M -5.77M -255M EV / Sales 2024
-42.8x
EV / Sales 2025 -32.3x
Free-Float
73.7%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 57 27/11/2015
Director of Finance/CFO 62 27/09/2022
Chief Tech/Sci/R&D Officer 60 01/09/2022
Director TitleAgeSince
Chairman 57 27/11/2015
Director/Board Member 69 16/01/2020
Director/Board Member 47 01/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%-1.17%+1.05%+6.39% 50.35B
+0.03%-4.56%+375.03%+585.49% 39.21B
+2.09%+0.49%+32.38%-5.14% 34.52B
+1.49%+4.62%+13.49%+60.09% 34.6B
+1.68%-0.62%+3.30%+27.34% 27.05B
-0.86%-3.66% - - 16.68B
+1.28%-0.42%+69.37%+115.57% 15.11B
-0.06%+0.70%+14.59%+17.94% 13.85B
+0.42%+1.53%+18.96%-30.07% 13.18B
Average +0.50%+0.94%+66.02%+97.20% 27.17B
Weighted average by Cap. +0.51%+0.83%+78.69%+120.77%

Financials

2024 2025
Net sales 72.1K 63.04K 58.15K 53.46K 101K 6.94M 103K 694K 272K 3.39M 271K 265K 11.69M 72.1K 63.04K 58.15K 53.46K 101K 6.94M 103K 694K 272K 3.39M 271K 265K 11.69M
Net income -4.39M -3.84M -3.54M -3.26M -6.17M -423M -6.28M -42.3M -16.6M -207M -16.5M -16.14M -712M -4.23M -3.7M -3.41M -3.13M -5.94M -407M -6.04M -40.71M -15.97M -199M -15.88M -15.53M -685M
Net Debt -7.08M -6.19M -5.71M -5.25M -9.95M -681M -10.12M -68.18M -26.75M -333M -26.59M -26.01M -1.15B -6.86M -6M -5.53M -5.09M -9.64M -660M -9.8M -66.04M -25.91M -323M -25.76M -25.19M -1.11B
Logo GOLD SWAP
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Employees
-